Compare INGN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | PLX |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 168.4M |
| IPO Year | 2013 | 1996 |
| Metric | INGN | PLX |
|---|---|---|
| Price | $6.57 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $11.25 | ★ $12.00 |
| AVG Volume (30 Days) | 221.8K | ★ 677.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $348,668,000.00 | $52,744,000.00 |
| Revenue This Year | $8.03 | $36.81 |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | $10.50 |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $1.41 |
| 52 Week High | $9.13 | $3.19 |
| Indicator | INGN | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 60.49 |
| Support Level | $6.00 | $2.06 |
| Resistance Level | $6.72 | $2.42 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 36.75 | 58.70 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.